Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study

Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 inhibitor that is currently used to treat patients with type 2 diabetes mellitus. The aim of the present study was to evaluate the safety and efficacy of tofogliflozin add‐on to glucagon‐like peptide‐1 (GLP‐1) receptor agonist monotherapy.

[1]  M. Davies,et al.  Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  S. Del Prato,et al.  Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes , 2017, Drugs.

[3]  J. Whaley,et al.  Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. , 2011, Kidney international. Supplement.

[4]  M. Ohmori,et al.  Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2012, Journal of medicinal chemistry.

[5]  A. Mehta,et al.  Liraglutide for weight management: a critical review of the evidence , 2016, Obesity science & practice.

[6]  Y. Terauchi,et al.  Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study , 2014, Cardiovascular Diabetology.

[7]  J. Camargo,et al.  Glycated albumin: a potential biomarker in diabetes , 2017, Archives of endocrinology and metabolism.

[8]  Y. Terauchi,et al.  Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials , 2014, Expert opinion on pharmacotherapy.

[9]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[10]  T. Fukuzawa,et al.  Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice , 2012, Journal of Pharmacology and Experimental Therapeutics.

[11]  R. DeFronzo,et al.  The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia , 2012, Diabetes, obesity & metabolism.

[12]  N. Papanas,et al.  Tofogliflozin: the road goes ever on , 2014, Expert opinion on pharmacotherapy.

[13]  É. Hardy,et al.  Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. , 2016, The lancet. Diabetes & endocrinology.

[14]  M. Humayun,et al.  Addition of SGLT2 inhibitor to GLP‐1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control , 2016 .

[15]  R. Poole,et al.  Tofogliflozin: First Global Approval , 2014, Drugs.

[16]  M. Kakuda,et al.  The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study , 2017, Journal of clinical medicine research.

[17]  J. J. Gorgojo-Martínez,et al.  Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[18]  R. DeFronzo,et al.  Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. , 2015, American journal of physiology. Renal physiology.

[19]  D. Yabe,et al.  Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events , 2015, Expert opinion on drug safety.

[20]  D. Sutton,et al.  Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. , 2014, Drugs of today.

[21]  C. McAdam-Marx,et al.  SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives , 2016, Vascular health and risk management.

[22]  Young In Park,et al.  Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes. , 2017, American health & drug benefits.

[23]  André Rodrigues,et al.  Mellitus , 2018, Proceedings of the 17th International Conference on Mobile and Ubiquitous Multimedia.

[24]  R. Busch,et al.  SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[25]  Diana M. Isaacs,et al.  A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond , 2015, Drugs in context.

[26]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[27]  T. Kadowaki,et al.  A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus , 2015, Diabetes, obesity & metabolism.

[28]  K. Utsunomiya,et al.  Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post‐marketing study (J‐STEP/EL Study) , 2017, Journal of diabetes investigation.

[29]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[30]  Joseph M Pappachan,et al.  Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience , 2016, Endocrine.